Blinatumomab

證據等級: L5

預測適應症: 10 個

Blinatumomab: From B-Cell Precursor Acute Lymphoblastic Leukemia to Primary Release Disorder of Platelets

One-Sentence Summary

Blinatumomab (Blincyto) is a CD19×CD3 bispecific T-cell engager (BiTE) antibody established for the treatment of relapsed/refractory B-cell precursor Acute Lymphoblastic Leukemia (ALL). The TxGNN model predicts it may be effective for Primary Release Disorder of Platelets, but the 2 identified clinical trials both address B-ALL treatment rather than platelet function — neither is designed to evaluate the predicted indication. This prediction is currently assessed as a knowledge graph false positive with no supporting biological rationale or direct clinical evidence.

Quick Overview

Item	Content
Original Indication	Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
Predicted New Indication	Primary Release Disorder of Platelets
TxGNN Prediction Score	95.20%
Evidence Level	L4
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current evidence pack. Based on known information, Blinatumomab is a bispecific T-cell engager (BiTE) antibody that simultaneously binds CD19 on B-lymphocytes and CD3 on T-lymphocytes, physically redirecting cytotoxic T cells to recognize and destroy CD19⁺ B-cell precursors. Its efficacy in relapsed/refractory B-cell precursor ALL has been established through multiple international Phase 2 and Phase 3 clinical trials.

The apparent connection between Blinatumomab's established indication (B-ALL) and primary release disorder of platelets is indirect. Patients with B-ALL routinely develop thrombocytopenia — either from disease-related bone marrow infiltration or as a consequence of chemotherapy. This co-occurrence in the clinical literature has likely positioned these two conditions as network neighbors within the TxGNN knowledge graph, creating a statistical association that does not reflect any shared pathophysiology or therapeutic target.

Primary platelet release disorders involve dysfunction in platelet dense granule or alpha-granule secretion pathways, which operate entirely within the platelet-megakaryocyte axis and are mechanistically independent of the CD19⁺ B-cell / CD3⁺ T-cell immune axis that Blinatumomab engages. No published preclinical or clinical data supports a pharmacological link between BiTE-mediated B-cell depletion and correction of platelet granule release defects.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04524455	Phase 1b	Completed	17	Safety and tolerability of Blinatumomab + AMG 404 in R/R B-ALL; primary objective was estimating MTD/RP2D of AMG 404. Platelet counts collected as safety monitoring only, not as an efficacy endpoint.
NCT03476239	Phase 3	Completed	121	Multicenter Phase 3 study of Blinatumomab efficacy in Chinese adults with R/R B-precursor ALL; primary endpoint was hematological response (CR/CRh). Platelet parameters are safety monitoring, not therapeutic targets.

⚠️ Relevance caveat: Both trials are B-ALL studies (relevance grade C). Neither investigates platelet release disorder as a therapeutic indication. Association with the predicted indication is system-generated and not clinically meaningful.

Literature Evidence

Currently no related literature available.

Singapore Market Information

Blinatumomab holds no product registrations in Singapore. The drug is not currently marketed or authorized for any indication under HSA.

Cytotoxicity

Blinatumomab is an antineoplastic immunotherapy approved for a hematological malignancy. The following applies:

Item	Content
Cytotoxicity Classification	Targeted therapy / Immunotherapy — CD19×CD3 BiTE antibody; not a conventional cytotoxic chemotherapy agent
Myelosuppression Risk	Moderate to High — B-ALL patients are at baseline high risk; cytokine release syndrome (CRS) can transiently worsen neutropenia and thrombocytopenia during therapy
Emetogenicity Classification	Low — immunotherapy mechanism; not classified as a conventional emetogenic agent
Monitoring Items	CBC with differential (baseline and during infusion), liver function, renal function, neurological status (mandatory neurotoxicity monitoring), electrolytes, CRS surveillance (temperature, blood pressure, oxygen saturation)
Handling Protection	Standard biologic (protein-based therapeutic) handling precautions; Blinatumomab is not classified as a hazardous cytotoxic agent under NIOSH guidelines and does not require cytotoxic drug handling protocols

Safety Considerations

Safety data (key warnings and contraindications) was not available in the current evidence pack.

Please refer to the package insert for complete safety information. It is noted that Blinatumomab carries a black-box warning in its FDA-approved labeling for Cytokine Release Syndrome (CRS) and Neurological toxicity, both of which can be severe or life-threatening. These require careful review before any clinical application, regardless of indication.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction of Blinatumomab for primary release disorder of platelets is biologically implausible under current evidence. The drug's CD19×CD3 BiTE mechanism has no established pharmacological connection to platelet granule secretion pathways, and the two identified clinical trials address B-ALL management — platelet values appear only as safety monitoring parameters, not therapeutic endpoints. The high TxGNN score (95.20%) reflects knowledge graph proximity between B-ALL complications and platelet disorders, not genuine mechanistic or clinical overlap.

To proceed, the following is needed:

Identification of any published mechanistic link between CD19⁺ B-cell depletion or T-cell engagement and platelet granule release function — currently none is known
Complete safety profile review including FDA/EMA black-box warnings for CRS and neurotoxicity before any expanded indication assessment
Review of published B-ALL trial datasets for any secondary findings documenting improvement in platelet function beyond simple count recovery
HSA/Singapore regulatory pathway feasibility assessment, noting that the drug is not currently approved or marketed in Singapore
MOA data retrieval from DrugBank (DG002) and TFDA package insert (DG001) to enable formal mechanistic plausibility scoring
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.